More research and clinical studies on the medical use of cannabis are needed because existing evidence about its potential therapeutic benefits is often insufficient, according to the European drug agency.
In its first major study on the topic, the European Monitoring Centre for Drugs and Drug Addiction said that there were limitations and important gaps in much of the research to date. It claimed that evidence for the benefits of cannabis as a treatment for a range of diseases and symptoms was weak to moderate in most cases.
“This emphasises the need for additional research and clinical studies, including larger and better-designed trials, studies looking at dosage and interactions between medicines and studies with longer-term follow-up of participants,” the agency said.
The centre expressed concern…